Compare Global X MSCI Argentina ETF (ARGT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs Sanofi SA — how do they compare? Global X MSCI Argentina ETF trades at $91.07, while Sanofi SA trades at $43.74 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| ARGT | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $52.34 |
52-Week Low | $67.55 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT is trading at $91.95, down 1.58% today amid bearish technical signals. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $92. Recent Seeking Alpha analysis (June 18, 2026) highlights Argentina's economic reforms creating potential for 28% upside, though financial ratios remain undisclosed. The fund's concentration in MercadoLibre presents both opportunity and risk as Argentina's monetary backdrop improves.
The outlook suggests cautious optimism with reform progress driving potential re-rating, though technical weakness and single-country concentration require careful risk management. Near-term performance hinges on Argentina's economic stabilization and institutional investor confidence, with Stanley Druckenmiller's recent position (Q1 2026) indicating sophisticated investor interest.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
